New drug combo could help kidney transplant patients stay healthier
NCT ID NCT05938712
First seen May 04, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study tests whether taking two common diabetes and heart drugs together (dapagliflozin and semaglutide) is safe and helpful for people who have received a kidney transplant. About 20 adults who are at least 3 months post-transplant will take the drugs for 12 weeks. The goal is to see if the combo improves kidney function and reduces stress on the kidneys.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT RECIPIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Toronto General Hospital
RECRUITINGToronto, Ontario, M5G 2N2, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.